Journal
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume 37, Issue 6, Pages 783-787Publisher
WILEY
DOI: 10.1002/hed.23655
Keywords
Rendu-Osler-Weber syndrome; hereditary hemorrhagic telangiectasia (HHT); avastin
Categories
Funding
- Roche Austria
Ask authors/readers for more resources
BackgroundThe purpose of this study was to investigate the efficacy of bevacizumab (Avastin) for the treatment of epistaxis in hereditary hemorrhagic telangiectasia (HHT). MethodsIn this double blind, placebo controlled trial, 15 adult patients with HHT with a minimum of 2 epistaxis episodes per week were randomized. A history of thromboembolic events or recent or planned surgery led to exclusion. Patients received a single intranasal submucosal injection (10 mL) of 100 mg bevacizumab or placebo. The primary outcome was the relative reduction of average daily epistaxis visual analog score (VAS). ResultsAverage daily posttreatment VAS scores decreased by 27% in the bevacizumab group and by 3% in the placebo group (p = .57). The reduction in HHT epistaxis severity scores was -0.61 greater in the bevacizumab group compared to the placebo group (p = .34). ConclusionResults show a trend toward reduced epistaxis with bevacizumab. This further supports the use of bevacizumab in HHT. Clincial Trials. gov number: NCT01314274 (c) 2014 Wiley Periodicals, Inc. Head Neck 37: 783-787, 2015
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available